Extended Summary
AIM ImmunoTech
Elon Musk is seeking damages of up to $134 billion from OpenAI and its long-time backer Microsoft. He claims he deserves the “wrongful gains” both companies received from his early support. The latest tranche of Epstein files contradict Musks 2019 claims. AIM ImmunoTech to present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Report will be on the birth and impending death of our money system. Barry L. Ritholtz: We have a few politicians who are well known to be Members for the electorate of Rinehart AIM ImmunoTech to participate in live ‘Fireside Chat on Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET. Thomas K. Equels will participate in a moderated ‘fireside’ chat that will focus on AIMs clinical and regulatory strategy for its lead drug. AIM ImmunoTech reports positive year-end interim clinical progress from phase 2 study evaluating Ampligen® (rintatolimod) in combination with astrazeneca’s imfinzi® (durvalumab) for the treatment of pancreatic cancer. Stephen Miller immediately claimed that Pretti had been a terrorist intent on massacring ICE agents, while JD Vance blamed protesters and Democrats for the killing. Intercontinental Exchange (the parent company of the NYSE) is developing a platform aimed at 24/7 tokenized securities trading and settlement, potentially funded via stablecoins. Crypt exchange Gemini is closing shop in the UK, EU, and Australia and cutting a quarter of its employees. Gemini shares have fallen more than 7.5% on Thursday, recently changing hands at $677.